Is there a need for liver enzyme monitoring in people using gender-affirming hormone therapy?
Theresa A StanglChantal Maria WiepjesJustine DefreyneElfi ConemansAlessandra D FisherThomas SchreinerGuy T'SjoenMartin den HeijerPublished in: European journal of endocrinology (2021)
The incidence of liver injury is found to be very low. We, therefore, conclude that liver enzyme monitoring within the frame of the risk of liver injury due to hormone therapy is not necessary for a transgender population.